Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastillo-Ávila, Wilmar-
dc.contributor.authorPiulats, Josep M.-
dc.contributor.authorGarcía del Muro Solans, Xavier-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorCondom i Mundó, Enric-
dc.contributor.authorCasanovas i Casanovas, Oriol-
dc.contributor.authorMora, Josefina-
dc.contributor.authorGermà Lluch, José Ramón-
dc.contributor.authorCapellá, G. (Gabriel)-
dc.contributor.authorVillanueva Garatachea, Alberto-
dc.contributor.authorViñals Canals, Francesc-
dc.description.abstractPurpose: germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative. Sunitinib is an oral multitarget tyrosine kinase receptor inhibitor with antiangiogenic and antitumor activities. In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT. Experimental design: mice were implanted with four different testicular tumors: a yolk sac, two choriocarcinomas, and a CDDP-resistant choriocarcinoma variant induced in mice by continuous exposure to CDDP. Mice were treated with vehicle, CDDP, sunitinib, or the combination of both drugs and their effects on tumors were analyzed. Results: we observed a significant inhibition in tumor growth accompanied by longer survival after sunitinib treatment. Combination therapy with CDDP significantly enhanced these effects. Sunitinib induced apoptosis, reduced tumor cell proliferation and tumor vasculature, and inhibited vascular endothelial growth factor receptor 1, 2, and 3 and platelet-derived growth factor receptor α phosphorylation without affecting phosphorylation of other tyrosine kinase receptors. More importantly, tumor growth inhibition induced by sunitinib was also observed in the induced CDDP-resistant choriocarcinoma model. Conclusions: taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.-
dc.format.extent12 p.-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isformatofVersió postprint del document publicat a:
dc.relation.ispartofClinical Cancer Research, 2009, vol. 15, num. 10, p. 3384-3395-
dc.rights(c) American Association for Cancer Research, 2009-
dc.subject.classificationMedicaments antineoplàstics-
dc.subject.classificationQuimioteràpia del càncer-
dc.subject.classificationMalalties del testicle-
dc.subject.otherAntineoplastic agents-
dc.subject.otherCancer chemotherapy-
dc.subject.otherTestis diseases-
dc.titleSunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors-
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
576742.pdf1.58 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.